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Oxidized low-density lipoprotein (LDL) is thought to play an important role in the inflam-
matory response associated with human obesity. The purpose of this preliminary study
was to determine oxidized LDL concentrations in healthy dogs and cats, and to evaluate
whether obesity affects oxidized LDL concentration, using 39 cats and 19 dogs that
had visited two different veterinary clinics in Japan. We hypothesized that oxidized LDL
concentrations measured against body condition score (BCS) may have a potential value
in evaluating the qualities of accumulated or circulating lipids in obese dogs and cats
that do not show signs of metabolic diseases. The mean oxidized LDL value in BCS3
dogs (2.40.9µg/dl) was very similar to that of BCS5 dogs (2.20.3µg/dl). The mean
oxidized LDL value of BCS4 dogs was 7.210.3µg/dl and the highest among three
groups. BCS4 dogs included two dogs whose oxidized LDL values were higher than the
mean oxidized LDL value of healthy humans (11.20.3µg/dl). On the other hand, the
mean oxidized LDL value of BCS3 cats was 2.50.9µg/dl, and those of BCS4 and 5
cats were higher than that of BCS3, but there was no significant difference. The BCS4
cat group included one cat with a higher oxidized LDL value, and the BCS5 group also
included two cats with oxidized LDL values higher than the mean oxidized LDL value of
healthy humans. Interestingly, the oxidized LDL values in two obese dogs and three obese
cats were indeed higher than the mean oxidized LDL value of humans with coronary artery
disease (20.11.1µg/dl). In conclusion, this preliminary study showed reference ranges
of oxidized dogs and cats against BCS. Obesity alone does not appear to have any direct
effect on serum oxidized LDL values in healthy dogs and cats.
Keywords: oxidized LDL, dog, cat, ELISA, electrophoresis
Introduction
Hyperlipidemia can be characterized by quantitative increases in circulating lipoproteins or by
higher lipid concentrations of various lipoproteins classes. Obesity in dogs and cats is commonly
associated with hyperlipidemia. Generally, the treatment of hyperlipidemia in dogs and cats is to
reduce the intake of cholesterol and/or triglycerides (TG). Recently, the modification of lipids has
been identified as an important factor in human hyperlipidemia; therefore, it has been considered
more effective to inhibit the oxidization of low-density lipoprotein (LDL) rather than to reduce the
amount of cholesterol in humans (1). For instance, oxidized LDL is thought to play an important
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role in the inflammatory response. Oxidized LDL alters the bio-
logical properties of growth factors, cytokines, monocytes, and T
lymphocytes by modulating their production (2–8). Acute coro-
nary syndrome is triggered by the activation of immune-mediated
inflammatory processes with atherothrombosis (9–11). Some
reports indicated that highly oxidized LDL has been detected
in the plasma of coronary heart disease (CHD) patients (12–
14). Studies in laboratory animals and humans have shown that
oxidized LDL is a better predictor of atherosclerosis and cardio-
vascular disease. In animal studies, administration of antioxidant
drugs, like probucol, inhibits LDL oxidation and arterial plaque
formation, even when there is no change in blood cholesterol
levels (15–18). In fact, administration of the antioxidant buty-
lated hydroxytoluene (BHT) significantly reduces the degree of
atherosclerosis in the aorta of rabbits, even though it raises LDL
cholesterol levels (19).
By immunoassays, using murine monoclonal antibodies
prepared against malondialdehyde-modified LDL (MDA-LDL)
found in human plasma, higher concentrations of MDA-
LDL were found in the patients with CHD (13, 20). Elevated
concentrations of oxidized LDL are predictive of future CHD
events in apparently healthy men (21). Because CHD is the
leading cause of human death, there are many studies of oxidized
LDL causing CHD and/or arteriosclerosis. It was shown that
an increase in oxidized LDL level is the most important factor
associated with CHD (22).
It is commonly considered that dogs and cats rarely develop
atherosclerosis in the absence of metabolic disease (23). This is
due to the fact that high-density lipoprotein (HDL) levels in dogs
and cats are higher thanLDL,VLDL, and chylomicron levels. They
are considered to be HDL-dominant animals unlike humans (24).
Therefore, many veterinarians do not test for oxidized LDL levels
in dogs and cats. There are no oxidized LDL data of dogs and
cats with/without disease. There is no data available to evaluate
whether high concentrations of LDL or oxidized LDL are risk
factors for CHD.
However, this does not mean that dogs and cats do not develop
atherosclerosis. It has been reported that dogs develop severe
atherosclerosis when a plasma cholesterol concentration of over
750mg/dl persists for more than 6months (25). Some veterinar-
ians feel that as obesity in animals has increased in developed
countries, so will atherosclerosis, as seen in humans.
A retrospective report by Hess (26) showed that dogs with
atherosclerosis were over 53 times more likely to have con-
current diabetes mellitus than dogs without atherosclerosis.
By the same token, dogs with atherosclerosis were over 51
times more likely to have concurrent hypothyroidism than dogs
without atherosclerosis (26). Other studies have shown that
glomerulopathy is more prevalent in dogs with atherosclero-
sis compared to dogs without atherosclerosis (27). If we could
accurately measure and understand oxidized LDL concentra-
tions in dogs and cats, it may become a preventive marker
for metabolic syndrome, diabetes mellitus, hypothyroidism, and
glomerulopathy. The purpose of this preliminary study was to
investigate oxidized LDL concentrations and develop the nor-
mal ranges of oxidized LDL concentration in healthy dogs and
cats, and to evaluate how obesity affects the concentrations of
oxidized LDL.
Obesity is a clinical sign that develops as the first sign of
metabolic disease. When dogs and cats gain weight, their lipopro-
tein fractions are modified as well. Previously, we showed a spe-
cific elevation in HDL1 fraction, which plays an important role
in reverse cholesterol transport similar to LDL, in obese dogs,
and increased LDL concentrations of all fractions in obese cats
(24). Therefore, we hypothesized that oxidized LDL concentration
measured against body condition score (BCS) may have a poten-
tial value in evaluating the qualities of accumulated or circulating
lipids in obese dogs and cats that do not show clinical signs of
metabolic diseases.
We selected the following twomethods to measure and analyze
oxidized LDL: one was to determine the quantity of oxidized
LDL by ELISA, and the second method was to validate modi-
fied LDL (modified charged LDL) by lipoprotein electrophoresis
customized for dogs and cats.
Materials and Methods
Animals
This study consisted of 19 dogs and 39 cats that had visited
two different veterinary clinics (Ibaraki and Kanagawa) during
a 2-month period from the middle of November 2014 to the
middle of January 2015. The dogs utilized in the study included
8 females and 11 males, ages 1–16 years old, and the cat group
consisted of 22 females and 17 males, ages 0–15 years old. The
dog breeds represented were American cocker spaniel [female (F)
n= 1, male (M) n= 2], Chihuahua (F-1, M-1), Labrador retriever
(M-1), Maltese (M-1), Miniature dachshund (F-1, M-2), Shiba
(F-1), Shih tzu (F-1, M-1), Toy poodle (F-2), Yorkshire Terrier
(M-1), and Mixed breed (F-1, M-2). The cat group included
American shorthair (M-1), British shorthair (M-1), Norwegian
(F-2, M-1), Scottish Fold (M-1), and Mixed breed (F-20, M-13).
The subjects were diagnosed to be clinically healthy, according
to the physical examination, clinical signs, and biochemical data
evaluated by the attending veterinarians. These subjects did not
have hypothyroidism or diabetes mellitus. They received a BCS of
1–5 (28) based on palpation and inspection. The BCS applies a 5-
point scale: (1, very thin; 2, underweight; 3, ideal; 4, overweight;
5, obese). The resultant groups of dogs and cats were classified as
Normal (BCS3) and Obese (BCS4, 5).
This study was approved by the Nippon Veterinary and Life
Science University Animal Research Committee.
Blood Sampling
Postprandial blood samples (at least 4 h after the last meal)
were collected from the cephalic veins into serum separator
plastic tubes (Venoject II, Terumo Corporation, Tokyo, Japan).
They were centrifuged at approximately 300 rpm for 15min. In
accordance with an Ox LDL ELISA kit protocol, all samples
were aliquotted for oxidized LDL measurement to avoid loss of
bioactivity and contamination, and were stored at  20°C for no
more than 2months. They were not processed through repeated
freeze–thaw cycles.
Analysis of Serum Parameters
Serum lipid metabolites and enzyme activities were mea-
sured. Glucose (GLU), TG, total cholesterol (T-Cho), alanine
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TABLE 1 | Comparison of parameters in normal and obese animals.
Dog Normal Obesity High oxidized LDL dogs in obesity (n=2)
BCS3 dog (n=9) BCS4 dog (n=8) BCS5 dog (n=2)
Age (years) 6:5 3:6 9:0 6:4 12:5 0:7 13:5 0:7
BW (kg) 5:6 2:8 13:1 10:2 14:0 7:0 18:9 13:9
BCS (/5) 3:2 0:3 4:0 0:0a 5:0 0:0a 4:0 0:0
Glucose (mg/dl) 91:4 43:2 77:7 33:1 54:5 6:4 62:5 44:5
Triglyceride (mg/dl) 72:4 64:1 127:1 106:3 489:0 367:7 195:5 77:1
Total cholesterol (mg/dl) 183:0 50:8 212:8 39:1 288:0 72:1a 226:0 19:8
Oxidized LDL (µg/dl) 2:4 0:9 7:2 10:3 2:2 0:3 22:4 11:0
ALT (IU/l) 56:1 31:0 63:0 53:6 50:5 44:5 112:5 98:3
AST (IU/l) 35:2 8:3 33:4 14:8 23:5 3:5 33:5 12:0
Total protein (g/dl) 7:1 0:7 7:4 0:8 7:9 0:9 7:6 0:6
BUN (mg/dl) 17:2 6:4 17:0 4:4 17:5 4:9 19:0 9:9
Creatinine (mg/dl) 0:8 0:2 1:0 0:4 1:1 0:6 1:2 0:5
Values are presented as meansSD. BCS, body condition score.
High oxidized LDL dogs in obesity is animals with mean value of oxidized LDL greater than that of humans (11.2 0.3µg/dl)
a Indicates significance (Holm–Sidak One-way ANOVA, p<0.05) when BCS4 or 5 High ox LDL dogs were compared pairwise against BCS3 dog.
Cat Normal Obesity High oxidized LDL cats in obesity (n=3)
BCS3 cat (n=10) BCS4 cat (n=15) BCS5 cat (n=14)
Age (years) 1:0 1:2 6:9 5:1a 8:7 4:7a 12:3 3:8
BW (kg) 3:1 0:7 4:7 0:8a 6:7 2:2a 6:0 2:0
BCS (/5) 3:0 0:0 4:0 0:0a,b 5:0 0:0a 4:7 0:6
Glucorse (mg/dl) 168:4 43:0 130:2 57:9 122:5 70:9 153:0 35:4
Triglyceride (mg/dl) 37:5 19:3 66:1 41:8 152:6 218:3 71:7 11:6
Total cholesterol (mg/dl) 96:7 24:9 158:5 55:9a 168:1 50:0a 128:3 11:6
Oxidized LDL (µg/dl) 2:5 0:9 7:5 17:0 9:5 17:1 52:0 10:6
ALT (IU/l) 73:0 38:9 36:7 18:8a 47:8 30:4 54:5 7:8
AST (IU/l) 32:4 17:4 24:4 19:0 31:1 20:4 23:5 2:1
Total protein (g/dl) 7:3 0:4 7:9 0:6a 8:2 0:9a 8:9 0:1
BUN (mg/dl) 22:4 4:3 25:0 4:0 28:4 18:1 20:5 2:1
Creatinine (mg/dl) 1:2 0:3 1:5 0:3a 1:4 0:3 1:6 0:1
Values are presented as meansSD. BCS, body condition score.
High oxidized LDL cats in obesity is animals with mean value of oxidized LDL greater than that of humans (11.2 0.3µg/dl)
a Indicates significance (Holm–Sidak One-way ANOVA, p<0.05) when BCS4 or 5 cats were compared pairwise against BCS3 cat.
b Indicates significance (Holm–Sidak One-way ANOVA, p<0.05) when BCS4 cat were compared pairwise against BCS5 cat.
aminotransferase (ALT), aspartate aminotransferase (AST), total
protein, blood urea nitrogen (BUN), and creatinine (CRE) were
determined using a biochemical auto analyzer (JCA-BM2250,
JEOL Ltd., Tokyo, Japan) with the manufacturer’s reagents. Oxi-
dized LDL was determined using a Dog Oxidized low-density
lipoprotein ELISA (Kameyama Biomedical Company, WA, USA).
This ELISA kit uses a mouse monoclonal antibody for all of
malondialdehyde (MDA)-LDL, Nepsilon (carboxymethyl) lysine
(CML)-LDL, and detects advanced glycosylation end product
(AGE)-LDL; it cannot distinguish between them. We constructed
a calibration curve by plotting the average optical density for each
calibrator on the horizontal (X) axis against the concentration on
the vertical (Y) axis, and drawing the best-fit curve to generate a
four parameter logistic (4-PL) curve-fit.
Electrophoresis of Lipoprotein Cholesterol
Serum lipoprotein cholesterol profiles were measured by the
biphasic agarose gel electrophoresis method using a commercial
kit, Quick gel LIPO gels (Helena Laboratories, Saitama, Japan).
Agarose gel fraction bands were analyzed using customized
Epalyzer 2 Electrophoresis Processing Analyzer (Helena Labora-
tories, Saitama, Japan). In brief, 30µl of each sample was loaded
onto the gel, and run with a 14-min migration time at 250V
and 20°C. After migration, the gels underwent a 15-min reac-
tion time, followed by a 12-min decolorizing and a 30-s fixing
time. Cholesterol lipoprotein fractions were assessed and analyzed
using Edbank III analysis software (Helena Laboratories, Saitama,
Japan).
The band of modified LDL on electrophoresis migrates toward
the positive electrode when the charge of apo-lipoprotein in
LDL is modified. We set normal animals (BCS3) as control and
compared the band position of obese animals against each control
group.
Statistical Analysis
Values are expressed as mean SD. Statistical significance was
determined by Holm–Sidak One-way ANOVA. All tests were
performed using Sigmaplot version.11.2 (Systat Software Inc.,
San Diego, CA, USA). The significance level was set at p< 0.05.
The correlations were determined by Pearson’s product-moment
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FIGURE 1 | Serum oxidized LDL and total cholesterol concentrations among all dogs (A) and cats (B). This graph shows a correlation between total
cholesterol levels and oxidized LDL levels by Pearson’s product-moment correlation.
correlation coefficients, r, and are displayed as p< 0.05. The Elec-
trophoresis bands were assessed and analyzed using Edbank III
analysis software (Helena Laboratories, Saitama, Japan).
Results
The parametersmeasured in normal (BCS3) and obese (BCS4 and
5) animals are shown in Table 1. The T-Cho of BCS5 dogs was
significantly higher than that of BCS3 dogs, but other parameters
did not show significant differences. On the other hand, cats
showed significant differences in certain parameters. Age, BW,
T-Cho, and total protein of BCS4 and 5 cats were higher than
those of BCS3 cats. The ALT of BCS4 cats was significantly lower
than that of BCS3 cats, whereas the CRE value of BCS4 cats was
higher than that of BCS3 cats. Figure 1 shows the correlations
of T-Cho and oxidized LDL with BCS groups. Dog oxidized
LDLs that correlated with T-Cho were BCS3 (r= 0.4), BCS4
(r= 0.1), and BCS5 (r= 1.0). Cat oxidized LDLs that correlated
with T-Cho were BCS3 (r= 0.4), BCS4 (r= 0.1), and BCS5
(r= 0.3).
The oxidized LDL value in BCS3 dogs (2.4 0.9µg/dl)
was similar to BCS5 dogs (2.2 0.3µg/dl). The oxidized LDL
value of BCS4 dogs (7.2 10.3µg/dl) tended to be higher
than other BCS groups. The BCS4 group included two dogs
whose oxidized LDL values were higher than that of healthy
humans (11.2 0.3µg/dl) (29). The group consisted of one
Mixed breed (14-year-old female) and one Miniature dachshund
(13-year-old male).
On the other hand, the mean oxidized LDL value of BCS3
cats was 2.5 0.9µg/dl, BCS4 was 7.5 17.0µg/dl, and BCS5 was
9.5 17.1µg/dl; however, these increases were not significant.
BCS4 and 5 cats also included three cats with oxidized LDL
values that were higher than that of healthy humans. These cats
wereMixed breed (8-year-oldmale, 14-year-oldmale, 15-year-old
female). Figure 1 also shows the list of oxidized LDL dogs and cats
that were extremely high.
When we examined the lipoprotein fractions by electrophore-
sis, one obese dog and six obese cats had LDL peaks migrating
toward the positive electrode, unlike that of the controls. Repre-
sentative examples of degeneration fraction graphs with the LDL
migration of dogs and cats were as seen in Figure 2. The results
were not consistent with the quantitativemeasurement of oxidized
LDL. In fact, seven animals that had LDL fractions migrating
toward the positive side on electrophoresis did not have higher
oxidized LDL values on ELISA.
Discussion
Previous studies have shown that thyroid dysfunction is accom-
panied by changes in caloric intake and body weight, as well as
changes in the lipid profile. Hypothyroid rats showed significantly
decreased oxidized LDL levels, whereas hyperthyroid rats showed
significantly increased oxidized LDL levels (30). Another report
showed that oxidized LDL levels in 125 obese human patients were
positively correlated with body mass index and T-Cho concentra-
tion (31). The most recent report showed the presence of oxidized
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FIGURE 2 |Graphs of lipoprotein cholesterol separated by electrophoresis in obese dogs and cats. The upper curve represents the obese animal lipoprotein
cholesterol fraction, and the lower curve represents a normal animal lipoprotein cholesterol fraction. Left H is the LDL peak of obese animals. Right H represents the
origin. The electrophoresis bands were assessed and analyzed using Edbank III analysis software (Helena Laboratories, Saitama, Japan) and shown graphically.
LDL in human salivary samples and highlighted a correlation
between salivary and serum oxidized LDL levels. Moreover, sali-
vary oxidized LDL levels were higher in overweight/obese subjects
than in control subjects (32).
In this study, we were able to quantify oxidized LDL levels
in dogs and cats that had been diagnosed as healthy by their
veterinarians. These levels were approximately one-quarter of the
oxidized LDL value of healthy humans (11.2 0.3µg/dl) (29).
Dogs and cats are known as high HDL animals, in that HDL is
dominant, and the total amount of LDL is typically lower than
that of humans. Naturally, oxidized LDL levels in dogs and cats are
lower than that seen in humans. However, some obese dogs and
cats showed extremely high oxidized LDL values. The oxidized
LDL values in two obese dogs and three obese cats were indeed
higher than the mean value in humans (20.1 1.1µg/dl) with
coronary artery disease (29). Interestingly, the two high oxidized
LDL dogs were in the BCS4 group, not the BCS5 group. The three
high oxidized LDL cats were composed of one BCS4 cat and two
BCS5 cats, and the highest oxidized LDL cat was in BCS4 group.
This result suggests that BCS is not correlated with oxidized LDL
levels.
Limitations of this study include a small sample size for the
determination of reference ranges. Furthermore, the result of the
LDL fractionmigration by electrophoresis was not consistent with
the ELISA results. In humans, migration of the LDL fraction
peak toward the positive electrode is determined by the charge
of the LDL particle, reflecting both glycation and oxidation. This
is because the negative charge of apo B100 in LDL increases
by modifications, such as oxidation and glycation (33). A previ-
ous human study reported that plasma could be separated into
LDL sub-fractions [modified LDL (=oxidized LDL) and native
slow-migrating LDL] by capillary electrophoresis, and oxidized
LDL was shown as modified LDL. In this study, migration was
not clearly visible via this electrophoresis method, and further
studies using an appropriate electrophoresis method need to be
performed.
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Atherosclerosis is characterized by the accumulation of lipids
and cholesterol in the inner membrane and tunica media of arter-
ies (34). There are variations in lipoprotein metabolism among
animal species, and dogs are less likely to develop atherosclerosis
when compared to humans (35). Atherosclerosis is a cardio-
vascular and fibroproliferative inflammatory disease commonly
associated with age- and dietary-related factors in humans (36).
In a retrospective study of 21 dogs diagnosed with atherosclerosis
on postmortem examinations, Miniature Schnauzer, Doberman
pinscher, and Golden Retriever breeds were overrepresented,
possibly owing to the increased risk for dyslipoproteinemia in
these three breeds (37). Unfortunately, our obese high oxi-
dized LDL dogs were Miniature dachshund and Mixed breed.
In order to verify the breed predilection, more samples are
needed.
Atherosclerosis in dogs occurs secondary to chronic inflam-
matory diseases, such as hypothyroidism (38), diabetes mellitus
(39), hyperlipidemia (40), and dyspnea associated with obesity
(34). These diseases usually affect the brain, eyes, spinal cord,
heart, spleen, kidneys, lungs, pancreas, alimentary tract, and uro-
genital organs, such as prostate and urinary bladder (41). The
association between atherosclerosis and glomerular disease is well
established in humans (42). Interestingly, canine glomerulopathy
is more prevalent in dogs with atherosclerosis as compared to
dogs without atherosclerosis. Furthermore, canine atherosclerosis
accompanied by glomerulopathy contributes to an elevation in
serum cholesterol concentrations (27).
In this study, there was no significant difference in oxidized
LDL values between normal and obese animals, whereas there
were significant differences in T-Cho among BCS groups of dogs
and cats. The correlation between T-Cho and oxidized LDL did
not clearly show any trend. It suggests that obesity alone does
not have a direct effect on serum oxidized LDL values in healthy
dogs and cats. Onmeasuring oxidized LDL by electrophoresis, we
found that it is difficult to verify the migration of LDL fractions
as modified LDL. In future studies, oxidized LDL will be analyzed
by capillary electrophoresis, which will separate the LDL fractions
more clearly.
The association between atherosclerosis and glomerular disease
in humans is multifactorial. Human arteriosclerosis with renal
failure is shown to progress rapidly and has not been fully under-
stood. When renal failure is progressing, enhanced expression of
LOX-1 (receptor for oxidized LDL) is involved in the formation
of interstitial lesions in particular (43). However, oxidized LDL
may be a risk factor for chronic diseases in animals, such as
renal failure and diabetes mellitus. As a future study, we plan to
investigate whether inflammatory diseases (i.e., diabetes mellitus,
hypothyroidism, renal failure) can influence or induce different
changes in oxidized LDL and/or cholesterol lipoprotein fraction
ratios.
Unfortunately, this study has limitations. Only a small number
of dogs and cats could be included in each group; hence, results
and conclusions need to be interpreted with care. In order to
validate our results, a larger sample pool is needed.
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